Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
64679-0632-01 64679-0632 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0633-01 64679-0633 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0633-02 64679-0633 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0634-01 64679-0634 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0635-01 64679-0635 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0635-02 64679-0635 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0636-01 64679-0636 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
64679-0636-02 64679-0636 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
00078-0690-61 00078-0690 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
00703-3985-01 00703-3985 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 11, 2009 In Use
00703-3986-01 00703-3986 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 11, 2009 In Use
00781-3315-70 00781-3315 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous March 1, 2015 In Use
00781-3317-80 00781-3317 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous March 1, 2015 In Use
00781-9315-70 00781-9315 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2016 In Use
00781-9317-80 00781-9317 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2016 In Use
00955-1731-10 00955-1731 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 1, 2015 In Use
00955-1733-20 00955-1733 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 1, 2015 In Use
25021-0233-10 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use
25021-0233-20 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use
45963-0611-53 45963-0611 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 5, 2015 In Use
45963-0611-59 45963-0611 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 5, 2015 In Use
57277-0001-05 57277-0001 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 21, 2017 In Use
57277-0002-10 57277-0002 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 21, 2017 In Use
67184-0508-01 67184-0508 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 7, 2016 In Use
67184-0509-01 67184-0509 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 7, 2016 In Use
67184-0510-01 67184-0510 Oxaliplatin Oxaliplatin 200.0 mg/40mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 7, 2016 In Use
68083-0170-01 68083-0170 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 29, 2017 In Use
68083-0171-01 68083-0171 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 29, 2017 In Use
71288-0101-10 71288-0101 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 1, 2017 In Use
71288-0101-20 71288-0101 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 1, 2017 In Use
51808-0127-01 51808-0127 P32 Sodium Phosphate P32 Sodium Phosphate 5.0 mCi/mL Chemotherapy Radiopharmaceutical Phosphorus 32 Interstitial, Intra-Articular, Intraperitoneal, Intrapleural June 19, 2012 In Use
68083-0178-01 68083-0178 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 30, 2016 In Use
68083-0179-01 68083-0179 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 30, 2016 In Use
68083-0180-01 68083-0180 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 30, 2016 In Use
68817-0134-50 68817-0134 Paclitaxel Abraxane 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 10, 2005 In Use
70860-0200-05 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 In Use
70860-0200-17 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 In Use
70860-0200-50 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 In Use
00069-0187-21 00069-0187 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00069-0188-21 00069-0188 Palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00069-0189-21 00069-0189 Palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
63539-0189-11 63539-0189 Palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
00004-0365-09 00004-0365 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 1, 2011 In Use
00004-0365-30 00004-0365 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 1, 2011 In Use
00002-7640-01 00002-7640 Pemetrexed disodium Alimta 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan. 15, 2008 In Use
50242-0145-01 50242-0145 Pertuzumab Perjeta 30.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 8, 2012 In Use
59572-0501-00 59572-0501 Pomalidomide Pomalyst 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0501-21 59572-0501 Pomalidomide Pomalyst 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use

Found 10,000 results in 7 millisecondsExport these results